First Argenx’s Adhere trial in CIDP top line data readout was delayed and now the fda have delayed reviewing the subcutaneous version in gMG.
CSL shown right to not be panicking about anti fcrn threats.
- Forums
- ASX - By Stock
- CSL
- Anti fcrn threat seems to keep getting delayed
CSL
csl limited
Add to My Watchlist
0.02%
!
$198.37

Anti fcrn threat seems to keep getting delayed
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$198.37 |
Change
0.030(0.02%) |
Mkt cap ! $96.23B |
Open | High | Low | Value | Volume |
$200.98 | $203.69 | $198.37 | $647.4M | 3.086M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 428 | $198.37 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$198.40 | 360 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 428 | 198.370 |
2 | 35 | 198.360 |
5 | 166 | 198.350 |
21 | 475 | 198.340 |
6 | 547 | 198.330 |
Price($) | Vol. | No. |
---|---|---|
198.400 | 360 | 2 |
199.000 | 50 | 1 |
199.330 | 200 | 1 |
199.960 | 100 | 1 |
200.000 | 33 | 1 |
Last trade - 16.10pm 19/09/2025 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |